Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease

• Published in: Drug metabolism and disposition Vol. 38; no. 12; pp. 2293 - 2301
• Main Authors: Hardwick, Rhiannon N., Fisher, Craig D., Canet, Mark J., Lake, April D., Cherrington, Nathan J.
• Format: Journal Article
• Language: English
• Published: Bethesda, MD Elsevier Inc 01.12.2010; American Society for Pharmacology and Experimental Therapeutics; The American Society for Pharmacology and Experimental Therapeutics
• Subjects: Adult; Antioxidants - metabolism; Biological and medical sciences; Disease Progression; Fatty Liver - enzymology; Fatty Liver - pathology; Gastroenterology. Liver. Pancreas. Abdomen; Glutamate-Cysteine Ligase - analysis; Glutamate-Cysteine Ligase - genetics; Glutathione - metabolism; Glutathione Transferase - analysis; Glutathione Transferase - genetics; Humans; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Medical sciences; NAD(P)H Dehydrogenase (Quinone) - analysis; NAD(P)H Dehydrogenase (Quinone) - genetics; NF-E2-Related Factor 2 - metabolism; Other diseases. Semiology; Pharmacology. Drug treatments; NQO1; GSSG; NAFLD; DAB; DCPIP; GST; CDNB; TBARS; MDA; NASH; GCL; GCLC; ARE; Nrf2; ROS; GCLM; HNE; ERK; Human; Clinical stage; Enzyme; Non alcoholic steatohepatitis; Digestive diseases; Hepatic disease; Antioxidant

Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mec...